3 recruiting. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 3 |
| Phase 1 | 1 | Recruiting 1 |
Follow Malignant Ascites: new trials by email Literature Review of Malignant Ascites trials Research Report on Malignant Ascites
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy liposomal irinotecan monotherapy, Liposomal Irinotecan + rmhTNF-NC, Liposomal Irinotecan + Bevacizumab - Malignant Ascites | Phase 1 / Phase 2 | Recruiting | Dong sheng Zhang | 48 | 2025-11-28 | 2026-02-09 |
| The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant Ascites serplulimab, Bevacizumab, rmhTNF-NC - Malignant Ascites | Phase 2 | Recruiting | Sun Yat-sen University | 60 | 2023-12-14 | 2024-05-30 |
| A Clinical Trial With Apatinib for Subjects With Refractory Malignant Ascites Apatinib - Malignant Ascites, Apatinib | Phase 2 | Recruiting | The First Affiliated Hospital of Bengbu Medical University | 120 | 2017-01-01 | 2026-09-03 |
Bevacizumab (2) · Immune Checkpoint Inhibitors (1) · apatinib (1) · irinotecan sucrosofate (1) · recombinant human tumor necrosis factor-binding protein-1 (1)
Dong sheng Zhang (1) · Sun Yat-sen University (1) · The First Affiliated Hospital of Bengbu Medical University (1)
China (3)